{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:39:59Z","timestamp":1793158799789,"version":"4.5.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2021,5,1]]},"DOI":"10.1001\/jamaneurol.2021.0405","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T11:01:03Z","timestamp":1617015663000},"page":"558","source":"Crossref","is-referenced-by-count":229,"title":["Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study"],"prefix":"10.1001","volume":"78","author":[{"given":"Ludwig","family":"Kappos","sequence":"first","affiliation":[{"name":"Neurology and Research Center for Clinical Neuroimmunology and Neuroscience Basel, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering University Hospital and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fox","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Burcklen","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Freedman","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva K.","family":"Havrdov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hennessy","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Hohlfeld","sequence":"additional","affiliation":[{"name":"Institute of Clinical Neuroimmunology, Ludwig Maximilians University Munich, Munich, Germany"},{"name":"Munich Cluster of Systems Neurology (SyNergy), Ludwig Maximilians University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Lublin","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology, Multiple Sclerosis Center of Catalonia, Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pozzilli","sequence":"additional","affiliation":[{"name":"Sant\u2019Andrea Multiple Sclerosis Centre, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Scherz","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"D'Ambrosio","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies, Allschwil, Switzerland"},{"name":"Now with Clinical Research Department, Galapagos GmbH, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Linscheid","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vaclavkova","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Pirozek-Lawniczek","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilke","family":"Kracker","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies, Allschwil, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Sprenger","sequence":"additional","affiliation":[{"name":"Neurology and Research Center for Clinical Neuroimmunology and Neuroscience Basel, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering University Hospital and University of Basel, Basel, Switzerland"},{"name":"DKD Helios Klinik Wiesbaden, Wiesbaden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10130","key":"noi210009r1","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis.","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"noi210009r2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.2019.26.issue-1","article-title":"Multiple sclerosis\u2014a review.","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"issue":"20","key":"noi210009r3","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis.","volume":"343","author":"Confavreux","year":"2000","journal-title":"N Engl J Med"},{"issue":"14","key":"noi210009r4","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis.","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"noi210009r5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"issue":"5","key":"noi210009r6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"noi210009r7","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"noi210009r8","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"issue":"10127","key":"noi210009r9","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"noi210009r10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00415-009-0093-1","article-title":"The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.","volume":"256","author":"Hutchinson","year":"2009","journal-title":"J Neurol"},{"issue":"10","key":"noi210009r11","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis.","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol"},{"issue":"2","key":"noi210009r12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis.","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"noi210009r13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/S1474-4422(19)30391-6","article-title":"Advances in oral immunomodulating therapies in relapsing multiple sclerosis.","volume":"19","author":"Derfuss","year":"2020","journal-title":"Lancet Neurol"},{"issue":"1","key":"noi210009r14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/2040622315617354","article-title":"Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases.","volume":"7","author":"D\u2019Ambrosio","year":"2016","journal-title":"Ther Adv Chronic Dis"},{"issue":"2","key":"noi210009r15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1124\/jpet.110.176487","article-title":"The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation.","volume":"337","author":"Piali","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"noi210009r16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1124\/pr.110.003111","article-title":"International Union of Basic and Clinical Pharmacology: LXXVIII, lysophospholipid receptor nomenclature.","volume":"62","author":"Chun","year":"2010","journal-title":"Pharmacol Rev"},{"issue":"6","key":"noi210009r17","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bcp.2013.76.issue-6","article-title":"Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study.","volume":"76","author":"Brossard","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"noi210009r18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10928-014-9362-4","article-title":"Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator.","volume":"41","author":"Krause","year":"2014","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"noi210009r19","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1136\/jnnp-2013-307282","article-title":"Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.","volume":"85","author":"Olsson","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"noi210009r20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.v69.2","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"issue":"4","key":"noi210009r21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jval.2018.11.007","article-title":"Development and validation of the FSIQ-RMS: a new patient-reported questionnaire to assess symptoms and impacts of fatigue in relapsing multiple sclerosis.","volume":"22","author":"Hudgens","year":"2019","journal-title":"Value Health"},{"issue":"12","key":"noi210009r22","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/ni1545","article-title":"Finding a way out: lymphocyte egress from lymphoid organs.","volume":"8","author":"Schwab","year":"2007","journal-title":"Nat Immunol"},{"issue":"3","key":"noi210009r23","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/00004728-200105000-00022","article-title":"Normalized accurate measurement of longitudinal brain change.","volume":"25","author":"Smith","year":"2001","journal-title":"J Comput Assist Tomogr"},{"issue":"5","key":"noi210009r24","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1177\/1352458516659550","article-title":"Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.","volume":"23","author":"Sormani","year":"2017","journal-title":"Mult Scler"},{"issue":"10","key":"noi210009r25","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1177\/1352458515616701","article-title":"Inclusion of brain volume loss in a revised measure of \u2018no evidence of disease activity\u2019 (NEDA-4) in relapsing-remitting multiple sclerosis.","volume":"22","author":"Kappos","year":"2016","journal-title":"Mult Scler"},{"issue":"4","key":"noi210009r26","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/sim.v28:4","article-title":"A graphical approach to sequentially rejective multiple test procedures.","volume":"28","author":"Bretz","year":"2009","journal-title":"Stat Med"},{"issue":"5","key":"noi210009r27","doi-asserted-by":"publisher","first-page":"v46","DOI":"10.1007\/s00415-005-5008-1","article-title":"Multiple sclerosis trial designs for the 21st century: building on recent lessons.","volume":"252","author":"Lublin","year":"2005","journal-title":"J Neurol"},{"issue":"1","key":"noi210009r28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0022-510X(02)00312-X","article-title":"Quality of life in patients with multiple sclerosis: the impact of fatigue and depression.","volume":"205","author":"Janardhan","year":"2002","journal-title":"J Neurol Sci"},{"issue":"2","key":"noi210009r29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.neucli.2017.02.004","article-title":"Fatigue in multiple sclerosis\u2014insights into evaluation and management.","volume":"47","author":"Ayache","year":"2017","journal-title":"Neurophysiol Clin"},{"key":"noi210009r30","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fncel.2015.00460","article-title":"Fatigue in multiple sclerosis: neural correlates and the role of non-invasive brain stimulation.","volume":"9","author":"Chalah","year":"2015","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"noi210009r31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/ana.24018","article-title":"Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.","volume":"75","author":"Sormani","year":"2014","journal-title":"Ann Neurol"},{"issue":"3","key":"noi210009r32","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/1352458515593405","article-title":"Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice.","volume":"22","author":"Pichler","year":"2016","journal-title":"Mult Scler"},{"issue":"8","key":"noi210009r33","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1212\/WNL.0000000000001281","article-title":"Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.","volume":"84","author":"Radue","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"noi210009r34","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000390","article-title":"Teriflunomide slows BVL in relapsing MS: a reanalysis of the TEMSO MRI data set using SIENA.","volume":"4","author":"Radue","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"noi210009r35","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol"},{"issue":"6","key":"noi210009r36","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"issue":"3","key":"noi210009r37","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis.","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"noi210009r38","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment.","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol"},{"issue":"15","key":"noi210009r39","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1212\/WNL.94.15_supplement.1752","article-title":"Long-term efficacy and safety of ponesimod, an oral S1P1 receptor modulator: results from randomized phase ii core and extension studies in relapsing-remitting multiple sclerosis (1752).","volume":"94","author":"Freedman","year":"2020","journal-title":"Neurology"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2777917\/jamaneurology_kappos_2021_oi_210009_1620839776.21815.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T21:42:38Z","timestamp":1724708558000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2777917"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2021.0405","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}